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Objective: Women with multiple sclerosis are often
diagnosed and treated during their reproductive years.
Limited data are available on the safety of treatment
during pregnancy. The Betaseron Pregnancy Registry
prospectively monitored women exposed to interferon
β-1b (IFNβ-1b) during pregnancy to estimate the rates
of birth defects, spontaneous abortions (SABs) and
other negative outcomes in this population.
Design: From 2006 to 2011, this observational registry
enrolled women exposed prior to conception or during
pregnancy (but prior to or without abnormalities on
prenatal screening). Follow-up continued from
enrolment through the 4-month paediatric visit.
Setting: Patients in the USA who met these criteria
were enrolled in the registry.
Results: The registry enrolled 99 pregnant women;
3 were lost to follow-up. The earliest exposure to
IFNβ-1b occurred during the first trimester for 95
pregnancies and in the third trimester for 1 pregnancy.
There were 99 birth outcomes (3 twins), including
86 (86.9%) live births, 11 (11.1%) SABs and 2 (2%)
stillbirths. Birth defects were reported in five (5.1%)
cases. Rates of birth defects and SAB were not
significantly different from population comparators. No
developmental concerns were identified at the 4-month
paediatric visit.
Conclusions: The small sample size limits the ability
to draw definitive conclusions; however, there was no
pattern to suggest increased negative outcomes with
IFNβ-1b.
Clinical trials registration number: NCT00317564.
INTRODUCTION
Multiple sclerosis (MS) is a chronic demye-
linating and neurodegenerative disorder that
affects over 400 000 people in the USA.1 2
MS is much more common in women than
men, and diagnosis frequently occurs when
patients are in their 20s and 30s.3 4
Consequently, women of childbearing age
constitute a considerable portion of all
patients with MS. Furthermore, up to 10%
have disease onset during pregnancy.1
The approved disease-modifying treatments
(DMTs) for patients with MS have been given
pregnancy category ratings of B, C, D or X by
the US Food and Drug Administration (FDA)
based on clinical experience and/or preclini-
cal data (see table 1 for pregnancy categorisa-
tions of currently approved DMTs and a
definition of different pregnancy classifica-
tions).5–14 The safety of these agents during
pregnancy is a major concern given the
patient profile outlined above. However, data
on pregnancy outcomes in DMT-exposed
patients are limited. Among the β interferons,
Strengths and limitations of this study
▪ The Betaseron Pregnancy Registry contains the
largest sample of interferon β-1b-exposed preg-
nancies collected to date.
▪ The relatively small sample size limits the ability
to draw definitive conclusions; however, there
was no pattern to suggest increased negative
outcomes with interferon β-1b.
▪ Limitations of the Betaseron Pregnancy Registry
include the potential for under-reporting or dif-
ferential reporting of outcomes due to the exclu-
sion of retrospective patients and the voluntary
nature of participation.
▪ Birth defect ascertainment was limited to data
obtained from reporting healthcare providers;
infants were not examined directly as part of the
registry.
▪ Data on infant outcomes were only collected for up
to 4 months, reducing the ability of the registry to
measure developmental progress, defects diag-
nosed beyond 4 months of age, and resolution of
suspected defects reported in early infancy.
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this is particularly true for interferon β-1b (Betaseron/
Betaferon; Bayer HealthCare Pharmaceuticals; Whippany,
New Jersey, USA).
No teratogenic effects were seen in studies of pregnant
rhesus monkeys exposed to interferon β-1b. However,
dose-related abortifacient activity was seen at doses from
0.028 mg/kg/day to 0.42 mg/kg/day, which is 2.8–4.0
times the recommended human dose based on surface
area comparison.5 Although data on human exposure
during pregnancy are limited, patients are advised to dis-
continue treatment with interferon β-1b if they become
pregnant or plan to become pregnant.5 The goal of the
Betaseron Pregnancy Registry was to compare pregnancy
outcomes in women exposed to interferon β-1b at con-
ception or during pregnancy relative to general popula-
tion comparators. This is the largest observational study
reported to date for interferon β-1b.
METHODS
Population and outcome measures
The Betaseron Pregnancy Registry was a voluntary, pro-
spective, observational, exposure registration and
follow-up study. Women with an existing pregnancy who
had been exposed to interferon β-1b at any time after
the first day of the last menstrual period (LMP), or
during pregnancy but before any prenatal screening
(eg, ultrasound and amniocentesis), were prospectively
enrolled in the registry. Women with similar exposure
who had undergone some prenatal testing and were
without abnormal findings suggestive of fetal abnormal-
ities were also enrolled. Given the widespread use of
early prenatal testing, restricting enrolment to women
without prenatal testing would have dramatically
reduced the available population, hindering the success
of the registry.16 17 As retrospective cases (ie, pregnan-
cies submitted after the birth of the infant or after evi-
dence suggestive of an abnormality on prenatal tests)
can be biased towards reporting of unusual or severe
outcomes, these cases and those in which an abnormal-
ity was identified prior to registry contact were excluded.
The primary outcome measure was the rate of major
congenital malformations in infants exposed to inter-
feron β-1b during gestation, defined as any time after
the first day of the mother’s LMP. Secondary outcome
measures included the prevalence of spontaneous abor-
tion and other negative pregnancy outcomes in exposed
women. The prevalence of elective abortion, stillbirth,
ectopic pregnancy, neonatal death and maternal death
was assessed. Reporting was conducted by healthcare
providers (HCPs), patients or representatives of the
study sponsor. Maternal follow-up lasted from enrolment
through pregnancy outcome. Infant follow-up continued
through the 4-month paediatric visit in most cases.
Pregnancy outcomes were classified as live birth, spon-
taneous abortion, elective abortion or fetal death/
stillbirth. A live birth was defined as any delivery result-
ing in a viable neonate ≥24 weeks of gestation. The
spontaneous loss of a fetus at <20 weeks of gestation was
classified as a spontaneous abortion. Any fetus delivered
dead ≥20 weeks of gestation, or weighing ≥500 g regard-
less of gestational age, was classified as a stillbirth. Fetal
death occurring >20 weeks but <28 weeks was classified
as early fetal loss while death occurring ≥28 weeks was
considered late fetal loss. Elective abortions encom-
passed any induced or voluntary ending of the preg-
nancy. Other pregnancy outcomes included ectopic
pregnancies, maternal death and neonatal death. Infant
size was classified as ‘small’, ‘appropriate’ or ‘large’ for
gestational age based on HCP assessment.
Table 1 Pregnancy classifications of disease-modifying treatments (DMTs) approved for use by patients with multiple
sclerosis
Disease-modifying therapy Pregnancy category
Glatiramer acetate (Copaxone)9 B
Interferon β-1b (Betaseron/Betaferon; Extavia)5 14 C
Intramuscular interferon β-1a (Avonex)7 C
Subcutaneous interferon β-1a (Rebif)11 C
Fingolimod (Gilenya)8 C
Dimethyl fumarate (Tecfidera)13 C
Natalizumab (Tysabri)6 C
Mitoxantrone6 10 D
Teriflunomide (Aubagio)6 10 12 X
FDA pregnancy categories15
▸ Category A: No evidence of adverse effects in studies of pregnant humans
▸ Category B: No studies from humans, but no evidence of adverse effects in studies of pregnant animals; or negative effects
observed in animal models but no evidence of adverse effects in humans
▸ Category C: Insufficient evidence from human studies, but research with pregnant animals identified some
medication-related negative outcomes; in some situations, the medication may be more beneficial than harmful
▸ Category D: Medication-related negative outcomes in human studies but medication may be needed in some situations
▸ Category X: Medication-related negative outcomes in human or animal studies; there are no situations in which the
medicine should be used
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Birth defects were defined as any significant structural
or chromosomal defect diagnosed with signs/symptoms
using the Metropolitan Atlanta Congenital Defects
Program (MACDP) classification of birth defects, or any
case with two or more secondary or ‘conditional’ abnor-
malities that would not have been classified as primary
birth defects by the MACDP. Conditional abnormalities,
some of which were also referred to as ‘minor birth
defects’, were included if present in a cluster of two or
more to increase the sensitivity of monitoring and to
avoid missing a potential signal. Birth defects were coded
using an organ system classification to increase the possi-
bility of detecting a potential signal by grouping together
similar defects or defects with similar aetiology.18 All
cases were coded in accordance with the MACDP code
book and the organ system classification by an expert in
dysmorphology (AES) who evaluated the potential tem-
poral relationship between the exposure to interferon
β-1b and the aetiology of the defect, considering other
potential confounders (eg, exposure to other therapies
received during the pregnancy, maternal or paternal
history of defects, underlying disease).18 Further
follow-up for birth defect cases was conducted if add-
itional information was needed by the dysmorphologist
or the data safety monitoring board (DSMB). Defects
were classified as ‘defect with a known cause, temporality
may be irrelevant’; ‘no temporal association’ or ‘unable
to assess temporality’. Available data for each defect case
were reviewed individually for potential confounders and
relevant information was evaluated and recorded.
Conduct of the registry was overseen by an independ-
ent DSMB. The Betaseron Pregnancy Registry was listed
in the public trials registry (http://www.clinicaltrials.
gov) under NCT00317564.
Statistical procedures
Analyses were conducted on all prospective evaluable cases
(ie, enrolled pregnancies, not lost to follow-up, with known
outcome and birth defect status). The birth defect rate was
calculated by dividing the number of cases with birth
defects among all live births and fetal losses >20 weeks ges-
tation (numerator) by the number of live births (denomin-
ator). This approach increased the sensitivity of monitoring
and may have overestimated the true rate; however, it erred
on the side of caution. Since the presence or absence of
birth defects is difficult to ascertain among fetal losses,
including fetal losses in the denominator would have
biased the birth defect rate downwards. Ninety-five per cent
exact CI were calculated for birth defect rate and other
point estimates. Outcome data were stratified by the earliest
trimester of exposure to interferon β-1b.
Population-based external comparator groups were
used to evaluate the rates of spontaneous abortion and
birth defects in the registry. Risk of spontaneous abor-
tions was compared with estimates for the general popu-
lation of the USA from the National Survey of Family
Growth (NSFG), which was conducted by the National
Center for Health Statistics,19 using Fisher’s exact test
based on binomial distribution for exposures. Risk of
birth defects was compared with that reported by the
MACDP.20 21 This population-based birth defect surveil-
lance system includes all infants born in the metropol-
itan area of Atlanta, Georgia. From 1999 to 2003, the
MACDP estimated the population birth defect rate to be
2.78 birth defects/100 live births in its database.20 21
When the registry was designed and launched, it
aimed to enrol approximately 420 pregnant women to
reach the goal of 210 live births to evaluate the primary
endpoint (risk of birth defects). This sample size was
estimated to be sufficient to rule out a 2.2-fold increase
in birth defects compared with the MACDP rate of
2.7820 21 with 80% power (assuming a 5% level of signifi-
cance). The sample size goal of 420 pregnancies was
expected to result in only 210 live births because of
losses to follow-up, enrolment failures and a live birth
rate of 62%.17 After approximately 5 years of operation,
registry enrolment resulted in only 99 live births.
Role of the funding source
The study was jointly designed by members of the
DSMB and the study sponsor. The authors, which
included the DSMB and representatives of the sponsor,
had access to all the data, participated in analysis and
interpretation, and were members of the publication
committee. The decision to submit the article for publi-
cation was made jointly by the members of the steering
committee and the sponsor.
RESULTS
Patient disposition
Between 24 April 2006 and 31 July 2011, 99 pregnant
women were prospectively enrolled in the Betaseron
Pregnancy Registry. Follow-up of pregnant women and
their live-born infants continued through 16 July 2012.
Pregnancy outcomes were reported for 96 exposed preg-
nancies, with 3 pregnancies lost to follow-up (table 2).
Initial exposure to interferon β-1b occurred in the first
trimester for 95 patients, and in the third trimester for
1 patient. Seventy-four patients had paediatric follow-up.
For the remaining 22 patients, follow-up continued only
until birth. Prenatal testing prior to enrolment was
reported in 33 cases (34.4%).
The majority of the sample was Caucasian (62 patients
(64.6%)); 25 patients (26%) were African-American. In
addition, two patients (2.1%) were Hispanic while six
patients were of other races/ethnicities (6.3%) and
race/ethnicity data were missing for one patient (1%).
Note that the distribution of race/ethnicity in the
Betaseron Pregnancy Registry was different from popula-
tion norms in the USA (72.4% Caucasian, 12.6%
African-American, 16.3% Hispanic).22
Pregnancy outcomes
From the 96 evaluable pregnancies, there were a total of
99 birth outcomes available, including 3 sets of twins.
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These outcomes included 86 live births, 2 stillbirths and
11 spontaneous abortions (table 3). Both stillbirths
occurred in black women with a history of prior spon-
taneous abortion and other comorbidities that may have
affected birth outcomes. The first case, ending in still-
birth, reported hypertension, obesity (postgastric
bypass) and oligohydramnios. The second reported anti-
phospholipid antibody syndrome, maternal human
papillomavirus infection, early rupture of membranes
attributed to vaginal bacterial infection and preterm
labour and delivery attributed to incompetent cervix.
The prevalence of spontaneous abortion in the
Betaseron Pregnancy Registry (11.5% (95% CI 5.9 to
19.6)) was not significantly different from the 16% esti-
mate for the general population of the USA based on
NSFG data (relative risk 0.7 (95% CI 0.4 to 1.2), p=0.86;
Fisher’s exact test based on binomial distribution for
exposures).
Infant assessments were made at birth for 86 babies,
up to 3 months of age for 74 babies and at 4 months for
59 babies (table 4). HCPs assessed infant size as appro-
priate for gestational age at birth for 67 cases (77.9%).
Four-month follow-up did not identify any consistent
pattern of developmental abnormalities. Birth defects
were identified in five cases (table 5), resulting in a rela-
tive risk of 2.1 (95% CI 0.9 to 4.9). The reported birth
defects occurred in several different organ systems,
including the musculoskeletal, cardiovascular and circu-
latory systems, with no pattern to the organ systems
affected. For all cases reporting birth defects, the earliest
exposure to interferon β-1b 250 µg dosed every other
day occurred during the first trimester of gestation. No
birth defects were reported among the spontaneous
pregnancy losses or stillbirths. The birth defect rate esti-
mated by the Betaseron Pregnancy Registry (5.8% (95%
CI 1.9% to 13.0%)) was not significantly different from
that reported by the MACDP (2.78%, p=0.092, Fisher’s
exact test). The relatively wide CIs, which include the
MACDP rate, reflect the small sample size and suggest




Age at enrolment (years)
n 95*
Mean (SD) 30.9 (5.29)
Median (range) 31.0 (19–44)






















Prenatal tests, n (%)
Prenatal test(s) after enrolment 53 (55.2)
Prenatal test(s) prior to enrolment 33 (34.4)
Date of prenatal test(s) not provided 1 (1.0)
No prenatal tests 7 (7.3)
Missing/unknown 2 (2.1)
*Age data were missing for one case.
†First trimester exposure was initial exposure occurring from the
first day of the LMP through 13 weeks gestation; third trimester
exposure was initial exposure occurring in the 28th week through
the end of the pregnancy.
LMP, last menstrual period; MS, multiple sclerosis.
Table 3 Pregnancy outcomes in the Betaseron Pregnancy Registry
Outcomes, n (%, 95% CI) Interferon β-1b-exposed pregnancies Relative risk (95% CI)
Live births (N=96) 83 (86.4) –
Birth defects (N=86)* 5 (5.8, 1.9 to 13.0) 2.1 (0.9 to 4.9), p=0.092†
Spontaneous abortions (N=96) 11 (11.5, 5.9 to 19.6) 0.7 (0.4 to 1.2), p=0.8603‡
Stillbirth (N=96) 2 (2.1) –
Maternal deaths 0 (0) –
Infant deaths 0 (0) –
Ectopic pregnancies 0 (0) –
*Excludes spontaneous and elective abortions <20 weeks gestation with reported birth defects per Metropolitan Atlanta Congenital Defects
Program (MACDP) convention. The denominator is restricted to live births.
†Relative risk compared with 2.78% reported by MACDP; Fisher’s exact test based on binomial distribution for exposures.20 21
‡Relative risk compared with 16% rate of spontaneous abortion reported by National Survey of Family Growth (NSFG); Fisher’s exact test.23
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no difference between the birth defect rate from the
Betaseron Pregnancy Registry and the MACPD.
Owing to the relatively high percentage of black
patients in the Betaseron Pregnancy Registry, a subanaly-
sis of pregnancy outcome data was conducted to
compare black and non-black patients. No significant
differences were seen between these two populations in
the rates of birth defects or rates of spontaneous abor-
tion. However, small sample sizes in this subanalysis limit
the conclusions that can be drawn from these data.
DISCUSSION
This Betaseron Pregnancy Registry reported 99 out-
comes in 96 evaluable pregnancies (including 3 twin
pregnancies), consisting of 86 live births, 2 stillbirths
and 11 spontaneous abortions. There were five cases
with birth defects. Among these five cases were a variety
of birth defects which were not clustered around a
single type of defect or effected organ system. In add-
ition, two of these cases had defects that were not tem-
porally related to interferon β-1b exposure (ie, the
timing of the exposure was not consistent with the devel-
opment of the defect) and one had a chromosomal
abnormality potentially related to advanced maternal
age that was classified as having no temporal association
to exposure. This lack of consistent pattern suggests that
there was no signal for birth defects due to interferon
β-1b exposure. The risk of spontaneous abortion or
birth defect was not significantly different from com-
parator populations. In addition, no elective abortions
or maternal deaths were observed and there were no
abnormalities in rate of prematurity or in birthweight/
size. These data represent the largest cohort of inter-
feron β-1b-exposed patients reported to date; however,
the sample size was still smaller than necessary to have
sufficient statistical power to draw definitive conclusions.
To date, several publications have discussed the results
of exposure to interferon β formulations during preg-
nancy; however, none have exclusively examined inter-
feron β-1b exposure. A recent review of this literature
suggested that β interferons may be associated with some
negative outcomes,26 a conclusion that contrasts with the
findings presented here. Three studies, also with small
sample sizes (N=88, 69 and 23), found low birthweight in
infants exposed to interferon β formulations (either inter-
feron β-1a or β-1b) during gestation.27–29 Another study
(N=14) found evidence of prematurity with interferon β
exposure, but birthweight was not significantly lower than
unexposed comparators.30 However, another study (N=63)
Table 4 Infant assessments at birth and at 4 months
At birth At 4-month follow-up
Approximate median in
US population at birth24
Number of infants 86 59
Sex, n (%)
Female 40 (46.5) 26 (44.1)
Male 46 (53.5) 33 (55.9)
Infant weight, g
Median 3346.8 6747.0 3200–3600
Range 470.0–4593.0 4763.0–8902.0
Infant size, n (%)*
Small 7 (8.1) 3 (5.1)
Appropriate 67 (77.9) 48 (81.4)
Large 7 (8.1) 6 (10.2)
Missing 5 (5.8) 2 (3.4)
Infant length, cm
Median 50.8 63.5 49–50
Range 30.5–55.9 53.3–69.3
Infant head circumference, cm
Median 34.3 41.9 34.8–35.8
Range 29.5–38.1 37.0–44.5
Gestational age at birth, weeks
Median 39.0 NA
Range 24.0–41.0 NA
Gestational age at birth, n (%)†‡
Preterm 8 (10.0) NA 9.9%
Term 72 (90.0) NA
*Infant size relative to gestational age at birth and age at 4 months (±4 weeks), respectively.
†Gestational age at birth calculated as ((280−(corrected estimated due date−outcome date))/7); EDD was used when corrected EDD was not
available. Preterm births were defined as any baby born before the end of the 36th gestational week and term births were defined as those
born after ≥37 weeks, 0 days gestation.25
‡Among singleton live births; excludes three twin pregnancies (6 live births) with outcomes at 24 weeks, 5 days; 36 weeks, 3 days; and
36 weeks, 5 days.
EDD, estimated due date; NA, not applicable.
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did not find evidence of low birthweight following inter-
feron β exposure.31 Other negative pregnancy outcomes,
including a higher rate of spontaneous abortion and
shorter mean birth length, have also been associated with
exposure to interferon β formulations.27 28
In contrast, the Betaseron Pregnancy Registry did not
find any patterns to suggest negative pregnancy outcomes
associated with interferon β-1b exposure. It should be
noted that the five aforementioned studies combined par-
ticipants exposed to either interferon β-1a or β-1b into a
single group.27–31 Two of these studies did not provide sep-
arate numbers of interferon β-1a-exposed and
β-1b-exposed patients.27 29 In the three studies that divided
exposure groups into interferon β-1a and β-1b, patients
with interferon β-1b monotherapy exposure numbered
only 10–21,28 30 31 thereby limiting the statistical power to
draw conclusions about the effects of interferon β-1b on
pregnancy outcomes. The Betaseron Pregnancy Registry
data reported here have the advantage of a much larger
sample size (99 outcomes), albeit much lower than
planned when the registry was designed.
The Betaseron Pregnancy Registry included paediatric
follow-up, which has not been consistently reported in
other studies: only two other studies have assessed paedi-
atric outcomes.27 30 The first (N=14) reported normal
development of interferon β-1a-exposed or β-1b-exposed
infants up to the 12-month milestones (walking and
talking).30 A later study (N=88) found no developmental
abnormalities in interferon β-exposed infants after
2.1 years of follow-up.27 The Betaseron Pregnancy
Registry’s findings are consistent with these previous
reports and reinforce the hypothesis that there are no
obvious postnatal effects from in utero interferon β-1b
exposure.
The potential risks associated with interferon β-1b expos-
ure during pregnancy, which were not found to be signifi-
cantly different from comparator cohorts in this study,
need to be considered along with the risks for patients
with MS who remain untreated during pregnancy. Prior
research suggested that MS itself was not associated with
increased risk for negative pregnancy outcomes.1 However,
risk for relapses is higher after delivery, with 20–40% of
patients experiencing a clinical relapse or worsening of
the disease in the first 3 months postpartum.1
The results reported here are similar to two recent
presentations related to intramuscular interferon β-1a
exposure during pregnancy. In the first, no pattern sug-
gestive of increased negative outcomes was found in 306
pregnancies in the Avonex Pregnancy Exposure
Registry.32 Similarly, postmarketing surveillance (N=552)
found that the rate of spontaneous abortion was consist-
ent with the general population, with no evidence of
increased birth defect rates.33 Together with the
Betaseron Pregnancy Registry, the preponderance of
data suggest no pattern of increased negative outcomes
for women and infants exposed to interferon β formula-
tions during pregnancy, a finding that was supported by
a recent review of the literature related to interferon β
exposure during pregnancy (N=1105).34
This is also the first study to report on pregnancy
exposure outcomes in black patients with MS. No differ-
ences were noted based on race.
Limitations of the Betaseron Pregnancy Registry
include the potential for under-reporting or differential
Table 5 Summary of birth defect cases
Case Description of the reported birth defects* Organ system Temporality assessment
1 Live infant, male, 34 weeks gestation
Trisomy 21 (Down syndrome)† Chromosome anomaly Defect with known cause, temporality
may be irrelevant
2 Live infant, male, 40 weeks gestation
Haemangioma (capillary haemangioma parietal
area and left third toe)
Circulatory system Unable to assess temporality
3 Live infant, female, 39 weeks gestation
Hip dysplasia (defect) Other musculoskeletal
defects
Unable to assess temporality
Patent foramen ovale (conditional defect) Heart Defect with known cause, temporality
may be irrelevant
Patent ductus arteriosus (conditional defect) Circulatory system Defect with known cause, temporality
may be irrelevant
Ventriculoseptal defect (defect) Heart Defect with known cause, temporality
may be irrelevant
4 Live infant, male, 36 weeks gestation
Abnormal shape of the head without
craniosynostosis
Musculoskeletal defects No temporal association




*Gestational age data are birth ages, not age at exposure.
†The mother of this infant was older than 35 years of age.
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reporting of outcomes due to the exclusion of retro-
spective patients. However, it is important to note that
data from these retrospective patients were captured
through postmarketing surveillance efforts. In addition,
birth defect ascertainment was limited to voluntary
reports from HCPs (not unlike population-based public
health surveillance programmes), which potentially
limited the level of detail needed to fully characterise a
birth defect case and rule out missed or misdiagnoses.
Finally, data on infant outcomes were only collected for
up to 4 months, reducing the ability of the registry to
measure developmental progress.
Owing to low sample size, definitive conclusions cannot
be drawn from the Betaseron Pregnancy Registry data.
However, there was no pattern to suggest an increased risk
of birth defects in infants or an increased rate of spontan-
eous abortions in women after exposure to interferon β-1b
during pregnancy. Infant assessments, such as birthweight,
birth length and head circumference, also did not differ
from population estimates and the 4-month infant
follow-up did not identify any developmental concerns.
Continued monitoring through routine postmarketing sur-
veillance activities is recommended.
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